rare diseasesIdorsia launches redesigned Fabry disease trial with Nxera backingSwitzerland-based Idorsia has launched a new pivotal Phase 3 trial of lucerastat in Fabry disease, targeting kidney deposits after its first late-stage study failed to reduce nerve pain. The company … more ➔
fundraisingAtlas Bio launches with $12.5M to eliminate animal testing and simulate Phase 2 trialsSwitzerland-based Atlas Bio has emerged from stealth with $12.5 million in funding to develop AI simulations that predict drug responses, with the ambition of replacing parts of clinical development … more ➔
M&AFerring to buy fertility biotech Gameto for up to $1.38 billionSwiss pharma group Ferring Pharmaceuticals has agreed to acquire New York-based Gameto for up to $1.3825 billion (€1.24 billion), gaining a cell-based approach designed to shorten the hormone treatment … more ➔
Meanwhile in biotechNovartis drops Alzheimer’s program; Windward files for IPO; GSK wins hepatitis B approvalBeyond the main headlines, European biotech kept moving this week. This edition of Meanwhile in Biotech covers an Alzheimer’s program dropped from Novartis’ pipeline, a Swiss biotech’s Nasdaq ambitions, … more ➔
oncologyESMO 2026: The biggest announcements from European biopharmaThe European Society for Medical Oncology (ESMO) Congress is one of the biggest events on the cancer research calendar, where clinical results can reshape treatment decisions and drug developers’ prospects. … more ➔
clinical dataImmatics shows off its PRAME bispecific data at ESMO 2026Germany-based cancer immunotherapy specialist Immatics presented updated clinical data for two PRAME-targeted drug candidates at the ESMO Congress 2026 in Madrid. Particularly striking is the survival … more ➔
RadiopharmaceuticalsSpago Nanomedical seeks delisting to finance cancer drug developmentSweden’s Spago Nanomedical will ask shareholders on Nov. 19 to approve delisting from Nasdaq First North, arguing that its listing obstructs financing on acceptable terms for Phase 2a development of … more ➔
Deep DiveEurope takes cancer science into immunologyInspired by technology and insights gleaned from cancer research, Europe is leading the quest for a new generation of therapies in immunology and inflammation. Immunotherapy has revolutionised cancer … more ➔
ovarian cancerGenmab’s acquisition spree starts to pay off with new ovarian and colorectal cancer dataDenmark’s Genmab has reported that its antibody-drug conjugate rinatabart sesutecan (Rina-S) reduced the risk of progression or death by 71% and the risk of death by 57%, compared with conventional chemotherapy … more ➔
lung cancerRoche bets up to $813M on Zymeworks lung cancer candidateSwiss big pharma Roche has agreed to license ZW209, an experimental cancer immunotherapy from Vancouver-based Zymeworks, for $55 million upfront and up to $758 million more in conditional payments, plus … more ➔
